A new book is stirring debate across boardrooms by arguing that large U.S. companies are suffering from a hidden malaise that weakens results and saps morale. The work, published this month, says the problem touches many of the country’s most valuable firms and urges leaders to change course. It lands as growth slows, layoffs ripple through sectors, and investors press for better returns.
The core claim is stark and simple.
“A new book diagnoses a sickness affecting some of America’s biggest companies.”
While the book’s author has not been publicly identified in early summaries, the argument echoes long-running worries about bureaucracy, short-term thinking, and stagnant productivity. It also challenges leaders to rethink how they measure success.
Why This Argument Resonates Now
Concerns about corporate drift have been building for years. U.S. labor productivity growth cooled through much of the 2010s, even as firms invested in software and automation. Many companies now face higher capital costs, tighter labor markets, and fast-changing customer habits.
Research often cited by management analysts shows how fragile size can be. Innosight has estimated the average tenure of companies on the S&P 500 has fallen to about two decades, down from roughly three times that in the 1960s. Turnover at the top suggests that scale alone does not protect against missteps or slow adaptation.
Workforce engagement remains a pressure point. Gallup surveys have put U.S. employee engagement near one-third in recent years, a level that signals missed ideas and weaker execution. Remote and hybrid work added coordination challenges that many firms still are sorting out.
Symptoms the Book’s Critics and Supporters See
Though details of the book’s case are still emerging, executives and analysts point to recurring trouble signs:
- Bloated decision chains that slow product cycles and frustrate teams.
- Incentives tied to quarterly targets that crowd out long-term bets.
- Buybacks and dividends prioritized over research or worker training during good years.
- Compliance-heavy cultures that punish risk and dilute accountability.
Share repurchases highlight the tension. S&P 500 buybacks hit record levels in 2022, according to S&P Dow Jones Indices. Supporters say buybacks return excess cash and signal discipline. Critics say the practice can eclipse investment in people and innovation.
What Leaders and Workers Are Saying
Management voices split on the diagnosis. Some argue the real issue is not size but clarity. They say firms can grow and stay fast if they push decisions to the edges, set simple rules, and keep teams close to customers.
Others see a structural problem. They point to layers of vice presidents, overlapping committees, and risk controls that make even small changes hard. A senior engineer at a major manufacturer described roadblocks this way: “It takes months to approve a tool, and by then the need has changed.”
Workers push for clearer goals and less churn. Many say shifting priorities and reorganizations drain energy. Investors, meanwhile, ask for steadier plans, cleaner metrics, and proof that capital spending pays off.
Industry Impact and the Stakes
The argument matters because it shapes where dollars go. If leaders accept the diagnosis, they may trim middle layers, change bonus plans, and fund more product work. That could raise near-term costs but improve cycle times and customer satisfaction.
If they reject it, firms may stick with financial engineering and selective cuts to protect margins. That can keep earnings intact for a while, but the risk is slower renewal and loss of talent to younger rivals.
Examples from tech and retail show the swing. Companies that empower small teams and measure outcomes often ship updates faster and learn from users. Firms that centralize every call can ship less, miss shifts in demand, and become dependent on price cuts or promotions.
What to Watch Next
Three signposts will show whether the message is taking hold:
- Compensation plans that favor multi-year goals and customer metrics.
- Public commitments to reduce approval layers and cycle times.
- R&D and training budgets holding steady even as costs rise.
Boards will also face pressure to explain how strategy, culture, and capital use tie together. Investors increasingly ask for these links on earnings calls and in letters to shareholders.
The new book’s premise is blunt, and its timing is sharp. Whether the diagnosis proves right will depend on choices leaders make over the next few planning cycles. The safest bet for readers and investors is to watch incentives, decision speed, and sustained investment. Those signals will tell if America’s corporate giants are getting healthier—or if the illness is spreading.
